Clinical Trial

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 4, 2022 (before its estimated December 2, 2023 completion). Its status may not reflect the trial's current state.
Summary
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-02-20; most recent amendment 2022-10-02.
Status change: Not Yet Recruiting → Recruiting 2020-05-11
Trial Details
NCT Number NCT04280822
Lead Sponsor Henan Cancer Hospital
Conditions Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Enrollment 400 participants
Start Date 2020-04-21
Primary Completion 2023-12-02 (estimated)
Study Completion 2028-03-02 (estimated)
Updated on ClinicalTrials.gov 2022-10-04